GCIA
RNAM

Gabelli & Co Investment Advisers’s Avidity Biosciences RNAM Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-303,030
Closed -$21.9M – 332
2025
Q4 		$21.9M Buy
+303,030
New +$19.6M 3.28% 6

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Gabelli & Co Investment Advisers's RNAM Position: Q1 2026 in Review

Gabelli & Co Investment Advisers sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 303,030 shares — an estimated $21.9M sold.

Gabelli & Co Investment Advisers first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $21.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Gabelli & Co Investment Advisers reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 303,030 Avidity Biosciences shares in Q1 2026, an estimated $21.9M.
  • Gabelli & Co Investment Advisers first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Avidity Biosciences position peaked at $21.9M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.